 |
Prospector
Profile
3-25-004
|
| |
| Haber, Inc. |
NAICS |
334516 |
| 58 Medford Street,
Arlington, MA 02474 |
Description |
Analytical Lab. Instrument Mfg. |
| (781) 643-2727 |
Employees |
7 |
| http://www.haberscience.com |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-1.0700 |
| |
Assets |
(mil) |
0.9800 |
| |
Liability |
(mil) |
0.7600 |
| |
(for the year ended 2007-05-31) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Sullivan Bille P.C. expressed substantial doubt about the ability of Haber, Inc., to continue as a going concern after it audited the Company's financial statements for the year ended May 31, 2007. The auditor stated that the Company has suffered recurring losses from operations and has a working capital deficiency. The Company had a net loss of $1,071,719 for the year ended May 31, 2007, which is higher than the net losses of $879,179 and $737,177 during the years ended May 31, 2006 and 2005, respectively. As a result of its recurring losses, the Company's balance sheet at May 31, 2007 showed an accumulated deficit of $27,352,868.
|
| |
|
Intellectual Property:
A U.S. patent covering ElectroMolecularPropulsion(TM) EMP technology was granted to the Company's former Chairman and Chief Executive Officer, Norman Haber in 1976 and an extension of that patent was granted to Mr. Haber in 1979. The patents would have expired in April of 1993. However, recent changes in U.S. patents added three more years until 1996. While patents are pending on the current generation of EMP analytic instruments, the original patents covering the EMP technology, which were granted to Mr. Haber in 16 foreign countries and assigned to the Company, expired in 1996. The Company is in a position for prioritizing its advanced EMP and extraction technologies. It is engaged in investigative research which would enable the filing of additional patent applications relating to specific biotech aspects of the EMP technology with the U.S. Patent Office. In addition to patent protection filed or intended to be filed, the Company expects to rely on a material extent on selected un-patented proprietary know-how with respect to its various technologies. [SEC Filing 10-K 03-06-08]
|
| |
|
Description:
Haber, Inc., a scientific research and development company, operates in the areas of separation science, extractive metallurgy, and medical diagnostics.
|
| |
|
Officers:
Albert B. Conti (Chair, CEO & Dir.); Peter R. D'Angelo (EVP, CFO, Sec. & Dir.); Peter Tobia (Dir.)
|
| |
|
Auditor:
Sullivan Bille P.C.
|
| |
|
Securities:
Common Stock Symbol HABE.PK; Other OTC; 172,516,841 common shares outstanding as of November 30, 2007.
|
| |
| |
| |
| return to main page |
|
|
